Centene Corporation
CNC Healthcare Medical - Healthcare Plans NYSE
$41.82
+$0.73 (+1.76%)
Open: $41.26 | High: $41.88 | Low: $40.20 | Prev Close: Prev Close: $41.09
Market Cap: $20.56B
Volume: 6.2M | Avg: 6.4M
Last updated: April 24, 2026 at 08:01 PMInvestment Rating
Sell
Overall Score: 40/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 480
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | -3.09 |
| P/B Ratio | 1.03 |
| P/S Ratio | 0.11 |
| EPS | $-13.53 |
| Beta | 0.59 |
| Shares Outstanding | 491.77M |
| 52-Week High | $64.15 |
| 52-Week Low | $25.08 |
| SMA 50 | $38.34 |
| SMA 200 | $36.20 |
| Next Earnings | April 28, 2026 12:30 PM ET |
Financial Ratios
| Gross Margin | 12.2% |
| Operating Margin | -3.9% |
| Net Margin | -3.4% |
| ROE | -27.7% |
| ROA | -8.6% |
| Debt/Equity | 0.94 |
| Current Ratio | 1.68 |
| Quick Ratio | 1.68 |
Balance Sheet
| Total Assets | $77.66B |
| Total Liabilities | $57.60B |
| Total Equity | $19.95B |
|
|
|
| Cash | $17.89B |
| Total Debt | $18.78B |
| Net Debt | $889.00M |
Income Statement
| Revenue | $194.78B |
| Gross Profit | $23.83B |
| Operating Income | $-7,618,375,000 |
| Net Income | $-6,673,000,000 |
|
|
|
| EBITDA | $-5,140,375,000 |
| Revenue/Share | $396.64 |
Cash Flow
| Operating CF | $5.09B |
| CapEx | $767.00M |
| Free Cash Flow | $4.32B |
|
|
|
| Book Value/Share | $40.84 |
| Tangible Book/Share | $9.55 |
| Equity/Share | $40.63 |
Technical Indicators
| RSI (14) | 78.13 Overbought |
| MACD |
0.79
Signal: 0.18
|
| Volatility | 41.07% |
| Trading Signal | Overbought |
Performance & Returns
| 1 Year | +26.37% |
| Sharpe Ratio | 0.73 Fair |
| Volatility (Ann.) | 49.8% High Risk |
| CNC (1Y) | +26.37% |
| S&P 500 (1Y) | +14.41% |
| Alpha (Excess Return) | +11.96% |
Sector Comparison (Healthcare)
| Metric | CNC | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | -3.09 | 26.84 | 6% |
| P/B Ratio | 1.03 | -21.04 | 10% |
| ROE (%) | -27.74% | -9.32% | 12% |
| Net Margin (%) | -3.43% | 9.70% | 6% |
| Stock Score | 480 | 541.0 | 22% |
| 1Y Return (%) | +26.37 % | +4.70 % | 80% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CNC | $41.82 | $39.58 | $38.96 | $38.29 | $38.31 | $36.22 | 78.13 | 0.79 | 41.07% | 252445 | Strong Long | Bullish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the CNC stock
News Sentiment
| Ticker | Headline | Sentiment | Source | URL |
|---|---|---|---|---|
| CNC | Will Declining Memberships Weigh on Centene's Q1 Earnings? | Neutral | zacks.com | Read More |
| CNC | Centene (CNC) is a Top-Ranked Value Stock: Should You Buy? | Neutral | zacks.com | Read More |
| CNC | Centene Foundation Reports $34.9 Million Invested in Community Health, Education and Social Services in 2025 | Neutral | prnewswire.com | Read More |
| CNC | Superior HealthPlan Employees Contributed More Than 3,000 Volunteer Hours Across Texas Communities in 2025 | Neutral | prnewswire.com | Read More |
| CNC | Los Angeles Residents to Gain Faster Access to New Affordable Housing through Health Net's $10 Million Investment in "Guarantee Fund" | Positive | prnewswire.com | Read More |
Recent Insider Trading
| Date | Insider | Position | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-04-15 | MCNALLY TANYA M | officer: Chief People Officer | SELL | 964 | $37.26 | $35919 |
| 2026-03-15 | SMITH SUSAN RAYE | officer: Chief Operating Officer | SELL | 2918 | $34.45 | $100525 |
| 2026-03-15 | MCNALLY TANYA M | officer: Chief People Officer | SELL | 2785 | $34.45 | $95943 |
| 2026-03-15 | LONDON SARAH | director, officer: Chief Executive Officer | SELL | 36061 | $34.45 | $1242301 |
| 2026-03-15 | KOSTER CHRISTOPHER | officer: Secretary & General Counsel | SELL | 9087 | $34.45 | $313047 |
| 2026-03-15 | CASSO KATIE | officer: Corporate Controller & CAO | SELL | 3359 | $34.45 | $115718 |
| 2026-03-15 | Asher Andrew Lynn | officer: Chief Financial Officer | SELL | 15241 | $34.45 | $525052 |
Company Information
Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
| CEO | Sarah London |
| Employees | 60400 |
| Country | US |
| IPO Date | 2001-12-13 |
| Exchange | NYSE |
| Website | https://www.centene.com |
| Sector | Healthcare |
| Industry | Medical - Healthcare Plans |
Similar Stocks (Healthcare - Medical - Healthcare Plans)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category